Navigation Links
Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB
Date:5/6/2009

STOCKHOLM, May 6 /PRNewswire/ -- Axelar AB today announced successful completion of the single-day oral dosing part of its ongoing phase I/II clinical trial on cancer patients with its new anti-cancer drug AXL1717,an insulin-like growth factor-1 (IGF-1) receptor inhibitor which has no effects on the closely related insulin receptor. The study is conducted in Sweden on patients having terminal cancer disease. The results showed that a single-day dosing of AXL1717 could be successfully escalated with excellent tolerability. No dose-limiting toxicity was reported. The next part of the trial has now been approved, including a seven-day dosing BID regimen instead of single-day BID treatments. The first patients have already been treated with AXL1717 for seven days.

The ongoing phase I/II clinical trial is primarily designed to assess the safety, tolerability, and pharmacokinetics of the drug. As a secondary objective, anti-cancer effects are documented whenever possible.

"We are very pleased that high doses of AXL1717 could be administered to patients without significant side effects during the single-day treatments.", says Johan Harmenberg, CEO of Axelar AB. "Targeting cancer cells with AXL1717 instead of conventional cytotoxic chemotherapy may be a new and well-tolerated treatment alternative for cancer patients in the future."

The IGF-1 receptor is a promising target for the treatment of cancer, since the receptor is crucial for the survival and growth of malignant cells. In contrast, the IGF-1 receptor is not absolutely necessary for growth of normal cells.

AXL1717 is a small-molecule IGF-1 receptor inhibitor with no effect on the important and almost identical insulin receptor. Pre-clinical data show an extraordinary anti-tumor efficacy in animal models, including apparent complete tumor regression, for a wide range of human cancers such as breast cancer, prostate cancer, malig
'/>"/>

SOURCE Karolinska Development AB
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Symphony Medical Announces First Patient Successfully Treated With Novel Congestive Heart Failure Therapy
2. Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals
3. VeraSun Energy Selects Valero as Successful Bidder for Seven Facilities
4. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
5. EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology
6. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period
7. DiFUSION Technologies Completes Successful Testing of Antimicrobial Spinal Implant
8. WaferGens SmartChip(TM) System Performance Successfully Demonstrated in Initial Phase of Alpha Testing Program
9. GlaxoSmithKline Successfully Completes Tender Offer for Shares of Genelabs Technologies, Inc.
10. Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation
11. Strativa Pharmaceuticals Announces Successful Completion of Bioequivalence Studies for Ondansetron Thin Film
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... BRIDGEWATER, N.J. , July 24, 2014 /PRNewswire/ ... focused on developing and commercializing therapeutic products for ... disease, today announces receipt of notice on July ... that the NYSE-MKT has accepted the CorMedix plan ... the NYSE-MKT. As a result, the NYSE-MKT is ...
(Date:7/24/2014)... July 24, 2014 1000 balances – ... input on customers’ weighing needs and expertly narrows down ... of balances, scales or even terminals. , First, ... smallest weight (or select readability instead) and define the ... additional selection criteria narrows down the list to models ...
(Date:7/24/2014)... As part of the long-term strategic approach, ... region during 2014 with potential global expansion. , "We ... DZS to manage our clinical trials globally and in ... R&D and President of SBI pharmaceuticals MENA, Dr. Riyadh ... a focus on utilizing eClinical software and flexible team ...
(Date:7/23/2014)... made great strides in saving China,s endangered national treasure, ... 65 giant panda reserves that have been established and ... 1596 pandas remain in the wild. , Breeding ... the panda by improving genetic diversity, avoid inbreeding and ... are these high-profile programs doing so far? , In ...
Breaking Biology Technology:CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2
... the Phase III Clinical Development and ... of THR-100 in Developing Countries, LEUVEN, Belgium, ... biotechnology company focused on vascular disease, today,announced the ... International Limited (Hyderabad, India) for the manufacture of,THR-100, ...
... Collaboration With CDC to Ensure US,s Preparedness ... Public Health Emergency, CAMBRIDGE, England and CAMBRIDGE, ... a leading,vaccine company, announced today that the US ... (Smallpox (Vaccinia) Vaccine, Live) vaccine,for protection against smallpox. ...
... Sept. 3 Leading neurosurgical device,developer Elekta ... and treatment devices, along with clinical workflow ... at the European,Association of Neurosurgical Societies (EANS) ... neurosurgeons and related medical professionals,will gather at ...
Cached Biology Technology:ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 2ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 3ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 4FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox 2FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox 3FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox 4FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox 5Elekta Demonstrates Commitment to Stereotactic Innovation at EANS 2Elekta Demonstrates Commitment to Stereotactic Innovation at EANS 3Elekta Demonstrates Commitment to Stereotactic Innovation at EANS 4
(Date:7/24/2014)... , July 24, 2014 /PRNewswire-iReach/ -- The Geneva ... from cardiac devices, has cut emergency room wait times ... San Diego (UCSD) Medical Center, according to a recent ... UCSD Emergency Departments are using the suite to access ... pacemakers or defibrillators. "Using Geneva,s technology platform ...
(Date:7/24/2014)... decreased by 45% on average over a 35 year ... study on the impact of humans on declining animal ... invertebrates such as insects, spiders, crustaceans, slugs and worms ... control for crops, decomposition for nutrient cycling, water filtration ... Science and led by UCL, Stanford and UCSB, ...
(Date:7/24/2014)... ply silent freeways, solar panels blanket rooftops and power ... howling winds and from the blazing desert sun. , ... and economically feasible to convert California,s all-purpose energy infrastructure ... Energy , the plan shows the way to ... that could create tens of thousands of jobs and ...
Breaking Biology News(10 mins):UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4
... perilous place for the endangered manatee. While the mammals ... poses a great danger to manatee numbers. Debborah Colbert, ... many manatees die and are seriously injured in collisions ... how manatees perceive their environment. Whether they can localize ...
... a remote region of the Russian mountains a previously unknown ... Lead Scientist Professor Hans Cornelissen and his Russian-Dutch team describe ... root belongs to the small alpine plant Corydalis conorhiza and ... through layers of snow. Given this novel behaviour, the scientists ...
... in the open-access, peer-reviewed journal PLoS ONE ... Seoul National University, Korea, report that by evolving a ... copulatory attempts, females of an Asian species of water ... the sexes. Instead, females only expose their genitalia for ...
Cached Biology News:Manatees can probably hear which directions boats approach from 2Newly discovered snow roots are 'evolutionary phenomenon' 2Hidden genitalia in female water striders makes males 'sing' 2